Objective-Genetic studies might provide new insights into the biological mechanisms underlying lipid metabolism and risk of CAD. We therefore conducted a genome-wide association study to identify novel genetic determinants of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Methods and Results-We combined genome-wide association data from 8 studies, comprising up to 17 723 participants with information on circulating lipid concentrations. We did independent replication studies in up to 37 774 participants from 8 populations and also in a population of Indian Asian descent. We also assessed the association between single-nucleotide polymorphisms (SNPs) at lipid loci and risk of CAD in up to 9 633 cases and 38 684 controls. We identified 4 novel genetic loci that showed reproducible associations with lipids (probability values, 1.6ϫ10 Ϫ8 to 3.1ϫ10 Ϫ10 ). These include a potentially functional SNP in the SLC39A8 gene for HDL-C, an SNP near the MYLIP/GMPR and PPP1R3B genes for LDL-C, and at the AFF1 gene for triglycerides. SNPs showing strong statistical association with 1 or more lipid traits at the CELSR2, APOB, APOE-C1-C4-C2 cluster, LPL, ZNF259-APOA5-A4-C3-A1 cluster and TRIB1 loci were also associated with CAD risk (probability values, 1.1ϫ10 Ϫ3 to 1.2ϫ10
C irculating levels of blood lipids have been consistently associated with risk of coronary artery disease (CAD). 1 However, whereas low-density lipoprotein cholesterol (LDL-C) is known to cause atherosclerosis and CAD, the role of circulating high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) in the development of atherosclerosis and CAD remains uncertain. 2, 3 In this context, the integration of population genetics and epidemiological approaches could help assess the etiologic role of HDL-C and TG levels in atherosclerosis and CAD. 4 By identifying novel genetic determinants of blood lipids, these integrated approaches can also help provide new insights into the biological mechanisms regulating lipid metabolism and identify potentially novel therapeutic targets for CAD. [5] [6] [7] See accompanying article on page 2084
Recent genome-wide association (GWA) studies have identified several new loci that influence circulating levels of blood lipids, with around 30 genetic loci showing reproducible statistical associations with circulating HDL-C, LDL-C and TG. [5] [6] [7] [8] [9] [10] [11] [12] However, given that a substantial proportion of the genetic variance for these traits remains unexplained, these loci are likely to represent only a small proportion of all genetic determinants involved in lipid metabolism. We therefore conducted an extended GWA study of LDL-C, HDL-C, and TG levels to identify novel genetic determinants of these traits and validated our associations in independent populations, including a population of Indian Asian descent. We also examined the association between genetic variants showing reproducible statistical association with lipid levels with risk of CAD.
Methods

Study Populations
GWA Metaanalysis of Circulating Lipid Traits
We used data from 8 study populations comprising up to 17 723 participants of white European descent. These are the EPIC-Norfolk subcohort (up to 2269 participants), the EPIC-Norfolk obese set (up to 1009 participants), the British 1958 birth cohort (Wellcome Trust Case Control Consortium controls-up to 1458 participants), the CoLaus study (up to 5226 participants), the Genetic Epidemiology of Metabolic Syndrome (GEMS) study (up to 1665 participants), a sample from the London Life Sciences Population (LOLIPOP) study (up to 813 participants), controls from the FUSION type 2 diabetes study (up to 1099 participants), and the SardiNIA Study of Aging (up to 4184 participants). Individual studies have been described in detail in recent reports and are summarized briefly in Supplemental Table  I , available online at http://atvb.ahajournals.org. 6, 9, 12 Selected descriptive characteristics of all study populations are also provided in Supplemental Table I . We used only data from the GEMS study 13, 14 for our GWA analysis of LDL-C, as the study comprises cases and controls of dyslipidaemia, defined by high and low percentiles of HDL-C and TG, respectively (Supplemental Table I ).
Lipid Replication Analyses
Our replication set encompassed individuals of white European descent from 8 studies comprising up to 37 774 participants. Individual studies are summarized in Supplemental Table II . Briefly, the replication set comprised the EPIC-Norfolk cohort 15 (up to 19 793 individuals who had DNA and lipid measurements available and did not overlap with the EPIC-Norfolk subcohort or obese set), controls from the Ottawa Heart Study 16 (up to 1445 participants), Fenland study 17 (up to 1402 participants), an additional subset of the LOLIPOP study 9 (up to 710 participants), British 1958 Birth cohort T1DGC controls 18 (2527 participants-there is no overlap with the control set from the original (Wellcome Trust Case Control Consortium substudy), Northern Finland Birth Cohort 1966 10 (up to 5138 participants), National FINRISK Study 7 (up to 910 participants), and Rotterdam study 7 (up to 5849 participants).
Case-Control Studies for CAD
For our CAD metaanalysis, we combined data from 9 studies comprising up to 9633 cases and 38 684 controls. These studies included 2 nonoverlapping case-control studies of CAD derived from the EPIC-Norfolk cohort, 15 (Wellcome Trust Case Control Consortium CAD study, 19, 20 Ottawa Heart Study, 16 MEDSTAR and PENN CATH studies, 21 and nested CAD case-control studies derived from the CoLaus study, 6 GEMS study 13, 14 and Rotterdam study. 7 Details of these studies are provided in Supplemental Table III .
Studies of Indian Asian Ethnicity
To examine the consistency of our novel association signals for lipids in an ethnically distinct population, we used 4 nonoverlapping subsets of Indian Asian participants from the LOLIPOP study, 9 collectively comprising up to 9665 participants (see Supplemental  Table II for details) .
Local ethics committees approved all studies, and all participants gave written informed consent. ducted in each study independently using either IMPUTE 22 or MACH 12 (Supplemental Table I ).
Replication Genotyping for Lipid SNPs
SNPs taken forward for replication for the 3 lipid traits were genotyped on the EPIC-Norfolk cohort using either the iPLEX Sequenom MassARRAY platform or allelic discrimination on an ABI 7900 instrument (TaqMan, Applied Biosystems, Warrington, UK). Criteria for genotyping quality are outlined in Supplemental  Table II . For the remaining 7 replication studies (Supplemental Table  II) , genotypes were available in silico using data from genome-wide SNP chips or imputation analyses (Supplemental Table II ).
Genotyping of Case-Control Studies for CAD
Genotypes were available for in silico testing of lipid SNPs for association with CAD risk for the 9 case-control studies described above (see Supplemental Table III for details).
Studies of Indian Asian Ethnicity
Genotypes were available for in silico testing of SNPs with circulating lipid levels for the 4 nonoverlapping subsets of the LOLIPOP study (Supplemental Table II ).
Statistical Analyses
GWA Metaanalysis of Circulating Lipid Traits
Sample and SNP quality control criteria and statistical analysis for each lipid trait was done within each study independently (Supplemental Table I ). For the initial GWA screen, analyses were done within study using a uniform analytic strategy. All lipid traits were natural log transformed before GWA analysis across studies. The choice of natural log transformation was guided by the shape of the phenotype distributions across studies, to minimize skew while also retaining a link to the original data-particularly for studies comprising selected populations. This transformation also provided an interpretable regression coefficient. Analyses were conducted using an additive model adjusted for age, sex, and geographical/ population covariables where appropriate. Association analysis for both imputed and genotyped SNPs was done using SNPTEST 22 (with the full posterior probability genotype distribution) or MERLIN. 12 Only SNPs with a minor allele frequency of 1% or more and with a posterior-probability score more than 0.90 were considered for these imputed association analyses. Criteria for imputation quality and genomic control parameters are outlined in Supplemental Table I .
We conducted a GWA metaanalysis by combining summary data from each of the 8 studies using a fixed-effects model and inversevariance weighted averages of ␤-coefficients with Stata, version 8.2. This provided us with a combined estimate of the overall ␤-coefficient and its standard error. Between-study heterogeneity was assessed with the 2 test. To optimize data quality, we analyzed only SNPs that passed sample and SNP quality control criteria in each of the 8 studies and that had a measure of association (␤-coefficient and standard error) in all 8 studies (see above for details). Data for 2 155 369 autosomal SNPs were available for analysis of circulating HDL-C levels, 2 154 923 for LDL-C, and 2 155 784 SNPs for TG. We also calculated an inflation factor () for each study, which was estimated from the mean of the 2 tests generated on all SNPs that were tested (Supplemental Table I ). The overall genomic control parameters 23 were 1.08, 1.07, and 1.06 in our metaanalysis for HDL-C, LDL-C and TG, respectively. These results suggest that unmodeled relatedness or population stratification is unlikely to materially influence our results.
For the 3 lipid traits (HDL-C, LDL-C and TG), we examined SNPs only at known, previously reported, and novel loci that had a combined PϽ1ϫ10 Ϫ5 (an arbitrary statistical threshold) in the metaanalysis and that did not show any heterogeneity among studies (PϽ0.1).
Replication Analyses for Lipid SNPs
For each novel locus, the SNP showing the strongest statistical association was taken forward for replication in stage 2. These comprised 40 SNPs in total: 11 for HDL-C, 13 for LDL-C, 15 for TG, and 1 for both HDL-C and TG. We conducted replication analyses in the EPIC-Norfolk cohort using linear regression using natural log-transformed lipid levels and an additive model with adjustment for age and sex. We combined these data with in silico replication sets from the other 7 studies using metaanalysis, as above, to obtain an overall estimate of association in the combined datasets. These analyses comprised adjustment for age, sex and population variables, as relevant (Supplemental Table II ).
Association Analyses for CAD Risk
Association analyses were done using either SNPTEST, 22 PLINK 24 or ProbABEL 25 for 8 studies with genome-wide SNP data available. Analyses for these studies comprised adjustment for at least age, sex and population variables (where relevant-see Supplemental Table III) . For the EPIC-Norfolk-2 case-control study, we used logistic regression and a log additive model adjusted for age and sex to test for association of novel lipid SNPs with CAD. We combined summary estimates (log odds ratios and standard errors) for each of the 9 studies using metaanalysis, as above, to obtain a combined estimate of the association between SNPs and risk of CAD for a log additive model.
Studies of Indian Asian Ethnicity
For association analyses of potentially novel lipid loci in Indian Asian individuals, we combined data from the 4 LOLIPOP subsets (Supplemental Table II ) using the metaanalytic strategy outlined above. We then conducted a formal assessment of the heterogeneity (Q statistic) between the 2 ethnic groups for our potentially novel lipid loci by comparing overall summary estimates from our white European and Indian Asian studies using metaanalysis, as above.
Results
Known Genes Influencing Lipids
For LDL-C, HDL-C, and TG levels, the strongest statistical association signals in our GWA metaanalysis were at loci previously implicated in lipid metabolism or those recently identified as potential lipid genes. 5 Table 1 lists the 28 SNPs with strongest statistical associations for the 3 lipid traits (PϽ1ϫ10 Ϫ5 ) with no detectable heterogeneity among studies (PϾ0.1) at these genetic loci. Eighteen SNPs at these known loci reached genome-wide statistical association (PϽ5ϫ10 Ϫ8 ) in our data. As expected, genes showing strong statistical associations with LDL-C included APOB, the APOE-C1-C4-C2 cluster, CELSR2, HMGCR, LDLR, PCSK9, and CILP2, whereas CETP, LIPC, LIPG, LPL, ABCA1, LCAT, GALNT2, and MMAB/MVK showed clear statistical associations with HDL-C. Likewise, the ZNF259-APOA5-A4-C3-A1 cluster, LPL, ANGPTL3, GCKR, TRIB1, and MLXIPL genetic regions were strongly associated with TG levels. Several genetic loci were associated with more than 1 lipid trait, including an SNP at the APOE-C1-C4-C2 cluster, which showed a strong association with all 3 traits (Table 1) .
Recently Identified and Novel Lipid Genes
We also found statistical evidence for potentially novel loci that may influence circulating levels of blood lipids. Supplemental Table IV lists SNPs showing the strongest statistical association  at 40 potentially novel loci with PϽ1ϫ10 Ϫ5 and no detectable heterogeneity among studies (PϾ0.1). None of these SNPs reached genome-wide statistical association in our metaanalysis. Therefore, to help validate statistical associations found at these potentially novel loci, we examined whether these SNPs showed statistical associations in additional population-based cohorts as part of a replication study (complete results for all 40 SNPs at this stage 2 replication validation step are given in Supplemental Table V) .
From our stage 2 analysis, we identified SNPs at 8 loci that showed evidence for independent replication (PϽ0.05) with 1 or more lipid traits and that showed directional consistency with the discovery studies and no material heterogeneity among studies (PϾ0.1). Table 2 summarizes the results for these SNPs. In a combined analysis of all studies (including the discovery GWA studies), 6 of these loci reached genome-wide statistical association (PϽ5ϫ10 Ϫ8 ). These were SNPs at the MYLIP/ GMPR and PPP1R3B loci for LDL-C; at the SLC39A8, TTC39B, and FADS1 loci for HDL-C; and at FADS1 for TG. We note that recently published reports have also found SNPs at the TTC39B and FADS1-FAD2-FADS3 loci to be associated with circulating HDL-C and HDL-C/TG levels, respectively. 5, 7 As they were included in our replication strategy, we have retained these SNPs in Table 2 to present the relevant data and confirm statistical associations at the genome-wide level in our combined analysis.
MYLIP-GMPR
SNP rs2142672 showed strong statistical association with LDL-C levels. The C allele (frequency, 74%) is associated with relatively higher levels of circulating LDL-C. The SNP lies in a distinct block of high linkage disequilibrium (LD) between 2 genes-myosin regulatory light chain interacting protein (MYLIP) and guanosine monophosphate reductase (GMPR) on chromosome 6p23 (Supplemental Figure If) . The illustration suggests that this SNP is correlated with other SNPs that also show similar patterns of statistical association and that cluster around the MYLIP gene (Supplemental Figure  If) . Our data confirm results from a recent study that also identifies this locus as one that influences LDL-C. 26 A recent report has also implicated MYLIP (IDOL) in the regulation of circulating LDL-C levels, by its induction of low-density lipoprotein receptor degradation via ubiquitination. 27 
PPP1R3B
SNP rs2126259 lies upstream of the protein phosphatase 1, regulatory (inhibitor) subunit 3B gene (PPP1R3B) on chromosome 8p23 and is statistically associated with circulating LDL-C levels. The A allele (10% frequency) is associated with relatively lower levels of circulating LDL-C. The LD structure of this region is modest with surrounding SNPs also showing statistical association (Supplemental Figure Ig) . The PPP1R3B protein is involved in the regulation of glycogen metabolism in both muscle and liver. 28 It is possible that its association with circulating LDL-C levels is a reflection of downstream effects on the bioavailability of TG. In addition, in support of our findings for LDL-C, this locus has also been shown to be associated with very-low-density lipoproteincholesterol levels. 26 
TTC39B
The C allele (14% frequency) of rs643531 at the tetratricopeptide repeat domain 39B (TTC39B) locus on chromosome 9p22 is associated with lower HDL-C levels ( Table 2) . SNP rs643531 lies within intron 1 of the TTC39B gene in a modest LD block that does not contain any other known or putative genes (Supplemental Figure Ic) . Again, several highly correlated SNPs in this region show statistical associations with HDL-C levels (Supplemental Figure Ic) in our genome-wide scan. Our data support results from a recent report showing statistical association between an SNPrs471364 -at this locus and HDL-C levels. 5 The 2 SNPs (rs471364 and rs643531) are correlated at an r 2 of 0.74 and show directional consistent associations. The function of the TTC39B gene in humans is presently unknown.
SLC39A8
SNP rs13107325 at the solute carrier family 39 (zinc transporter) member 8 (SLC39A8) locus on chromosome 4q22 shows strong statistical association with circulating levels of HDL-C (Table 2) . It is a nonsynonymous SNP located in exon 8 of the SLC39A8 gene, which produces a change in amino acid from alanine to threonine. The T allele (frequency 8%) is associated with relatively lower levels of circulating HDL-C and is not materially correlated with any other SNP across 100 kb of genomic sequence spanning the SLC39A8 gene in HapMap (Supplemental Figure Id) . This gene encodes a zinc transporter that has been shown to function in the cellular importation of zinc at the onset of inflammation, and its expression is induced by TNF-␣. 29 It is possible that the SLC39A8 molecule might be associated with HDL-C in an inflammatory context.
FADS1
SNP rs174548 at the fatty acid desaturase 1 (FADS1) locus on chromosome 11q12 shows strong statistical association with both HDL-C and TG levels. The G allele (30% frequency) is associated with relatively higher TG and lower HDL-C levels ( Table 2 ). The genomic context of this locus is illustrated in Supplemental Figure Ia and Ib. SNP rs174548 lies in a block of clear LD that also contains the C11orf9/10, FEN1 and FADS2/3 genes. Several highly correlated SNPs within this LD block show statistical association with these traits in our genome-wide scan (Supplemental Figure Ia and Ib), including 2 SNPs in the 3Ј untranslated region of the FADS1 gene. Our study supports findings from a recent report showing that an SNP-rs174547-at this locus is also associated with both HDL-C and TG levels. 5 SNP rs174548 in our study is highly correlated (r 2 0.8) to SNP rs174547 and shows directionally consistent associations. Fatty acid desaturases are involved in the metabolism of polyunsaturated fatty acids in humans, and SNPs at the FADS1/2 gene cluster have been linked to changes in the fatty acid composition of serum phospholipids in humans. 30 
Examination of Lipid Associations in an Indian Asian Population
In an exploratory analysis, and to provide a wider context for our studies, we examined whether our replicated loci (from Table 2 ) were also associated with the relevant lipid traits in a population of Indian Asian descent-stage 3. Table 3 shows the results of these analyses. Only 6 of the 8 SNPs were available for analysis in this population (SNPs at 2 loci-SLC39A8 and IGF2R/SLC22A1-were not present or poorly imputed-Supplemental Information). As expected, given the low statistical resolution for this study, we found evidence for independent replication (PϽ0.05) at only 3 loci in Indian Asian individuals-PPP1R3B for circulating LDL-C levels, FADS1 for circulating HDL-C and TG levels, and AFF1 for circulating TG levels. However, association signals for the other 3 loci (TTC39B, C5orf35 and MYLIP/GMPR) were directionally consistent between ethnic groups (Table 3) .
In a combined analysis of all studies (stages 1, 2, and 3), we identified an additional locus that reached genome-wide statistical association-AFF1-a novel locus for circulating TG (Pϭ3.1ϫ10 Ϫ10 (Table 3) ). SNP rs442177 lies in intron 10 of the AFF1 gene on chromosome 4q21 in a modest LD block with correlated SNPs showing similar levels of statistical association (Supplemental Figure Ie) . The A allele (60% frequency in white European populations) is associated with relatively higher levels of circulating TG. The AFF1 gene encodes a protein involved in the regulation of cyclindependent kinase inhibitor CDKN1B and may therefore be involved in cell cycle regulation. 31 Its function with respect to TG metabolism is unknown. For 3 of our 8 novel lipid loci, we did not observe a statistical association with lipids in the Indian Asian population, and for 2 SNPs data were not available (Table 3 ). These observations could denote limited statistical resolution, differences in LD patterns in Indian Asians compared with Europeans, or that there are no association signals at these loci in Indian Asian populations. However, in further exploratory analyses, examining association signals across a 10-kb region spanning these 5 SNPs in our studies, we found evidence indicating that additional association signals may be present at some of these loci (see Supplemental Information).
Association With Risk of CAD
Given the causal link between circulating LDL-C levels and risk of CAD, and the consistent associations between circulating levels of TG and HDL-C with subsequent risk of CAD, we assessed the association between these known, recently identified, and potentially novel genetic lipid loci and risk of CAD. Table 4 shows the association between these 36 SNPs The Stage 3 analysis for circulating HDL-C, LDL-C, and TG levels is based on data from up to 9665 participants from 4 subsets of the LOLIPOP study (see Supplemental Table II Table II) .
‡␤-Coefficients represent the change in circulating lipid level (natural log) per additional effect allele, adjusted for age and sex. linked to lipid metabolism in our data and risk of CAD in up to 9633 cases and 38 684 controls. As expected, and given the prior associations between these loci and blood lipids, a much greater proportion of these SNPs showed statistical associations with CAD risk at PϽ0.05 than expected by chance alone, taking into account any correlated SNPs (Table 4 ). We identified 6 genetic loci that showed both genome-wide statistical association with blood lipids and statistical association with CAD after adjustment for multiple testing (PϽ0.0013 after testing 36 SNPs) (Table 4) . Specifically, we confirm the association between variation at the CELSR2 20 and APOB genes and variation at the APOE-C1-C4-C2 cluster, which influence mainly LDL-C levels, and risk of CAD (Figure 1) . None of the genetic variants largely or specifically associated with HDL-C showed statistical association with CAD risk after correction for multiple testing. Notably, SNPs at the ZNF259-APOA5-A4-C3-A1 cluster-which reached genome-wide statistical association-and at the TRIB1 and LPL loci, which show strongest association with TG levels (Figure 2 ), were also statistically associated with risk of CAD after adjustment for multiple testing (Table 4 and Figure 1 ). The direction of association with CAD risk for all of these SNPs was consistent with their association with lipid levels (Table 1) . However, several of the SNPs at these loci were associated with more than 1 lipid trait ( Figure 2 and Table 1 ). Of note, only SNPs at CELSR2 and APOB showed specific associations with LDL-C. By contrast, only SNPs at the LPL locus showed clear associations with HDL-C and TG, but they were not associated with LDL-C in our studies ( Figure 2 and Table 1 ).
Discussion
Our studies have identified 3 novel loci (PPP1R3B for LDL-C, SLC39A8 for HDL-C, and AFF1 for TG) associated with variation in circulating LDL-C, HDL-C, and TG. We also provide strong statistical evidence for 6 loci that influence levels of blood lipids and risk of CAD. In addition to those that are largely associated with LDL-C concentrations, we show that genetic loci mainly associated with circulating TG are also associated with risk of CAD. Collectively, these studies potentially provide new insights into biological regulation of lipid metabolism and the etiology of CAD.
We provide robust statistical evidence for the association of 3 novel genetic loci with circulating LDL-C, HDL-C, and TG levels, in addition to confirming the recently reported novel associations for circulating LDL-C with SNPs at MYLIP/GMPR, HDL-C levels with SNPs at the TTC39B locus, and for both circulating HDL-C and TG levels at the FADS1 locus. 5, 26 The function of the 3 novel loci, PPP1R3B, SLC39A8, and AFF1, in lipid metabolism is not known. However, consistent with our results, a recent study has shown that PPP1R3B is also associated with very-lowdensity lipoprotein-cholesterol levels 26 . Fine-mapping and functional studies, including large-scale resequencing to help identify common and rare functional variants, 32 might help clarify the role of proteins encoded by these genes in lipid metabolism and relevant disorders.
Recent reports have identified several potentially novel loci for circulating lipids. 5, 7 One of these reports presents an updated metaanalysis and has used the same threshold for stage 2 SNP selection as our study (PϽ1ϫ10 Ϫ5 ). 5 By using this arbitrary threshold for selection, we will undoubtedly have missed some additional novel loci. For example, 1 report identified an SNP-rs1501908 -that lies between the TIMD4 and HAVCR1 loci and is reproducibly associated with circulating levels of LDL-C. We selected this SNP for stage 2 replication testing, but it did not reach statistical association in our stage 2 samples (Pϭ0.1) (Supplemental Tables IV and  V) . However, the association signal in our data is directionally consistent with that found in the original report. These findings suggest that further novel loci involved in the regulation of blood lipids exist-providing opportunities for additional insights into lipid biology and potential therapeutic targets-and therefore highlight the need for a more comprehensive analysis of all available studies to gain appropriate statistical resolution to identify these loci.
We identified 6 lipid genes that show strong statistical association with CAD risk. Associations at these loci were directionally consistent with their associations with blood lipids. Three of these are predominantly associated with circulating LDL-C levels-APOB, APOE cluster, and CELSR2-reiterating the causal link between LDL-C and CAD, 33 and as previously reported. 12, 20, 34 Interestingly, our variant at the APOE locus, rs4420638, was correlated (data not shown) with 1 of the canonical APOE variants (r 2 ϭ0.71 with E4) but showed no correlation with E2 (r 2 ϭ0.018), suggesting that other independent variants may contribute to the variation in LDL-C and risk of CAD.
Whereas previous studies and reviews have provided only suggestive or inconsistent evidence for the APOB locus and CAD risk, 12, 34 we confirm that common variation at the APOB locus is associated with risk of CAD-in line with the effect of rare, highly deleterious mutations at this gene. 35 However, some genes known to be implicated in Mendelian forms of hypercholesterolemia and more recently myocardial infarction, including LDLR and PCSK9 21, 36, 37 , showed only suggestive evidence for association with CAD risk in our data. Because of limited statistical power to detect associations, larger scale studies of these and other genetic variants that influence LDL-C levels may help reliably determine their association with CAD risk.
We also provide compelling statistical evidence that genetic variants at loci predominantly associated with both circulating blood TG and HDL-C are also associated with risk of CAD-specifically at the ZNF259-APOA5-A4-C3-A1 cluster, TRIB1, and LPL loci. The TRIB1 locus is a recently identified lipid gene that predominantly influences TG but is also associated with LDL-C and HDL-C. One previous report has shown suggestive evidence for an association between a SNP at this locus and CAD risk. 12 We provide convincing evidence for association with CAD risk in our studies. The LPL variant in our study (rs325) is in perfect LD with the known S447X variant-a gain-of-function mutation, which causes a 2-amino acid truncation in the enzyme and increases its activity. 38 Our data are consistent with these observations and suggest that LPL activity may be causally linked to CAD risk. By contrast, the CAD-risk variant we identified in the ZNF259-APOA5-A4-C3-A1 cluster was largely uncorrelated with variants at the APOA5 and related genes that have been previously linked to TG levels and CAD risk. 39 A recent systematic review of known genetic variants at the LPL locus and CAD risk provided only suggestive evidence for association with CAD risk. 40 Similarly, previous reports have provided only weak and inconsistent evidence to suggest that variation at the APOA5 cluster is implicated in CAD risk. 39, 41 Collectively, our data, based on an unbiased analytic framework, confirm that the LPL, TRIB1, and ZNF259-APOA5-A4-C3-A1 cluster are CAD susceptibility loci.
Importantly, consistent with the biological role of the LPL locus, 42 SNPs at this locus were not associated with LDL-C levels in our large scale analysis, suggesting that the association with CAD risk is independent of LDL-C. However, (Table 4) .
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other loci that were associated with CAD risk showed robust associations with potentially multiple lipid traits (including LDL-C). By contrast, some loci showed comparable magnitudes of association with 1 or more lipid traits but showed inconsistent magnitudes of association with CAD risk. These differences might be due to limited statistical power or the differential impact of comparable differences in these lipids on risk of CAD. Statistical analyses adjusting for these intermediate phenotypes (lipid levels) when examining SNP-CAD risk associations may help disentangle the impact of these genetic variants on lipid levels and CAD risk. However, these analyses would require large-scale prospective studies with information on genetic variants, biomarkers and subsequent disease risk, which are not available across most of the studies used in the current analysis. These lipid and CAD risk loci may also have pleiotropic actions. 5 As a result, interpretation of interpretation of these findings is complex. From a qualitative perspective, these findings may suggest that some, but not all, biological mechanisms involved in TG and HDL-C regulation and metabolism or their correlates (including atherogenic very-low-density lipoprotein remnant lipoproteins 43 ) may be implicated in the etiology of CAD. [43] [44] [45] In this context, these data suggest that therapeutic approaches that target specific lipid pathways might have a potentially greater impact on reducing risk of CAD-particularly in the context of our findings for the LPL locus.
None of the genetic loci showing reproducible and specific association with HDL-C levels (including CETP), showed strong evidence for association with CAD risk. Because of limited statistical power, in terms of the expected magnitudes of the associations among HDL-C levels, HDL-C SNPs, and CAD risk, 46 we may have missed HDL-C genetic loci that also show association with CAD risk. Furthermore, the functional relationship of HDL-C to CAD risk is inherently complex, and plasma concentrations of HDL-C are not always a reliable marker of reverse cholesterol transport or other biological functions of HDL, including antiinflammatory effects. 47, 48 We assessed the generalizability of our novel SNP-lipid associations in a population of Indian Asian ethnicity and found that there was directional consistency between the 2 populations for statistically associated SNPs, with no strong heterogeneity between the 2 ethnic groups. However, we only had limited statistical resolution to detect any differences in the magnitudes of these associations between ethnic groups. It will be important to fully characterize the associations among all known genetic regulators of blood lipids and their link to CAD risk in this and other ethnically distinct populations. Importantly, genetic epidemiological approaches may help determine whether the marked differences in the prevalence of some metabolic diseases among populations have a genetic basis. 49 In conclusion, our studies have identified 4 novel loci associated with variation in circulating lipid concentrations and indicate that, with the caveats outlined above, genetic variants that influence lipid concentrations (primarily those that are associated with circulating LDL-C or specific metabolic and regulatory pathways for both TG and HDL-C) are also associated with risk of CAD. These findings potentially provide new insights into the biological mechanisms underlying lipid metabolism and CAD risk. Figure 1 and Table 4 . Associations and effect sizes are based on stage 1 metaanalyses and natural logtransformed data (see Table 1 
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Supplement Material Exploratory analyses
To see whether there were other statistical signals present at the SLC39A8, TTC39B, C5orf35, MYLIP/GMPR and IGF2R/SLC22A1 loci in individuals of Indian Asian descent, we examined association summary statistics across a 10 kb region spanning SNPs from Table 3 in our studies.
There were no association signals present at the SLC39A8 or TTC39B loci for circulating HDL-c levels (data not shown). The SLC39A8 SNP rs13107325 is relatively rare (8% frequency) in white European individuals so it may not be present in individuals of Indian Asian descent. Indeed it is not present in individuals of Chinese, Japanese or Yoruban ethnicity in HapMap. Likewise, the frequency of SNP rs643531 at the TTC39B locus is 7% in Indian Asian individuals compared to 14% in white European participants ( Tables 2 and 3 ). The signal for this SNP was directionally consistent with data from white Europeans, so it is likely that we did not have had the statistical resolution to reliably detect an association in Indian Asians. For the C5orf35 locus we observed a nominal statistical signal at SNP rs4301182 for association with TG at P = 0.03 (β coefficient 0.031 (standard error 0.015)) that is directionally consistent with that seen for SNP rs6867983 in our white European samples. SNP rs4301182 is correlated to SNP rs6867983 at an r 2 of 0.81 in individuals of white European ethnicity in HapMap. For circulating LDL-c levels we did not observe any signals at the MYLIP/GMPR locus in Indian Asian individuals, however for the IGF2R/SLC22A1 locus there were putative statistical signals at two uncorrelated SNPsrs2065396 and rs3777409 (P = 0.03 and P = 0.04 respectively). This suggests that there may be associations present at this locus in Indian Asians.
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Supplementary Figure I The recombination rates and hotspots are defined by blue lines and are compiled from genotyping data. Positions of genes and genomic co-ordinates are shown below the plots. Plots were generated using SNAP (http://www.broad.mit.edu/mpg/snap) 27 * For the GEMS study, case and control participants were determined by triglyceride and HDL-c levels (see references 7, 8 for details). These traits therefore have truncated distributions and are not reported. * For CoLaus LDL-c levels were corrected for participants taking lipid-lowering medication by multiplying by a constant of 1.375. This was derived from an estimated average reduction of 37.5% obtained for circulating LDL-c levels, based on the most commonly prescribed medication 14 . 
